Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.61 |
| ▸ | FBP1 | P09467 | 2/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417822 | 0.98 | EGFR (0.65) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL1418427 | 0.97 | EGFR (0.64) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL19634086 | 0.94 | EGFR (0.58) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL1191094 | 0.92 | EGFR (0.68) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL7219084 | 0.88 | EGFR (0.65) | EGFRKDREPHB4FBP1ERBB2 | |
| SCHEMBL31038407 | 0.88 | EGFR (0.69) | EGFRKDREPHB4ERBB2EPHA2 | |
| SCHEMBL29535477 | 0.88 | EGFR (0.69) | EGFRKDREPHB4ERBB2EPHA2 | |
| SCHEMBL1190518 | 0.88 | EGFR (0.69) | EGFRKDREPHB4ERBB2EPHA2 | |
| SCHEMBL1190516 | 0.88 | EGFR (0.69) | EGFRKDREPHB4ERBB2EPHA2 | |
| SCHEMBL15106827 | 0.88 | EGFR (0.58) | EGFRKDREPHB4FBP1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731511-B1 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-8722694-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-05-13 | — | — | US | disclosed |
| US-20120329778-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-12-27 | — | — | US | disclosed |
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100069414-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20070185091-A1 | Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7220750-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1731511-A1 | BicyclischeI heterocycles, medicaments containing these compounds, their use and methods for the production thereof | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |
| US-6653305-B2 | For therapy of tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-25 | — | — | US | disclosed |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
| EP-1157011-A1 | 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051991-A1 | 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069414-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | RET, ROR1, JAK1 | EGFR 100/4885KDR 765/4885EPHB4 2120/4885 |
| US-20120329778-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | RET, ROR1, JAK1 | EGFR 100/4885KDR 765/4885EPHB4 2120/4885 |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, CYP11B2 | EGFR 417/4885KDR 2460/4885EPHB4 3407/4885 |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | CYP11B1, ROR1, RET | EGFR 75/4885KDR 1135/4885EPHB4 2435/4885 |
| US-20070185091-A1 | Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them | RET, ROR1, JAK1 | EGFR 100/4885KDR 765/4885EPHB4 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.